Brind.

Insilico Medicine presented Phase 1 data for its ISM6331 drug candidate.

2 reports, 1 independent Updated Jul 29

Gone quiet

Reports: 2
Developments: 2
Repetition: 0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Insilico Medicine presented Phase 1 data for its ISM6331 drug candidate.

Who's involved

What this event is mainly about

Insilico Medicine European Society for Medical Oncology

How it developed

Newest first. Tap a step to see who reported it.

Jul 29Insilico Medicine applied for Fast Track review for ISM6331.1 source
- manilatimes.net
Jul 27Insilico Medicine shared Phase 1 clinical data for ISM6331.1 source
- manilatimes.net

Keep exploring

The entities involved

Insilico Medicine
American biotechnology company

Nothing else this week.
European Society for Medical Oncology
Professional organisation

Nothing else this week.

Coverage

Newest first; wire copies grouped

Jul 29manilatimes.net
Jul 27manilatimes.netInsilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors